SLV308 for Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations
Public ClinicalTrials.gov record NCT00406588. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of SLV308 as Adjunct Therapy to Levodopa in Patients With Parkinson's Disease Experiencing Motor Fluctuations.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is a multicenter, randomized, double blind, parallel group study of 3 months' treatment with SLV308 administered as a monotherapy in patients with advance stage PD. An open label safety extension to this study is planned as a separate protocol for patients who are willing and eligible to participate.
Study identification
- NCT ID
- NCT00406588
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 295 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 30 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2007 (Type not available)
- Primary completion
- Apr 2008 (Actual)
- Completion
- May 2008 (Actual)
- Last update posted
- Feb 27, 2015
2007 – 2008
United States locations
- U.S. sites
- 15
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 223 | Birmingham | Alabama | — | — |
| Site 220 | La Jolla | California | — | — |
| Site 211 | San Francisco | California | — | — |
| Site 214 | Fort Lauderdale | Florida | — | — |
| Site 218 | Gainsville | Florida | — | — |
| Site 213 | Tampa | Florida | — | — |
| Site 219 | Augusta | Georgia | — | — |
| Site 221 | Chicago | Illinois | — | — |
| Site 216 | Kansas City | Kansas | — | — |
| Site 224 | Lexington | Kentucky | — | — |
| Site 212 | East Lansing | Michigan | — | — |
| Site 217 | St Louis | Missouri | — | — |
| Site 222 | Durham | North Carolina | — | — |
| Site 210 | Toledo | Ohio | — | — |
| Site 215 | Houston | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 72 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00406588, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 27, 2015 · Synced Nov 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00406588 live on ClinicalTrials.gov.